CareDx (STU:1K9) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1K9 CareDx Inc STU:1K9
73 GF Score
Price €33.00
GF Value €18.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CareDx FFO?

FFO (Funds from operations) only applies to REITs.

STU:1K9
73GF Score
CareDx Inc STU:1K9
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CareDx (STU:1K9) Overvalued in 2026?

Based on GuruFocus' analysis, CareDx stock appears to be overvalued. The current stock price of €33.00 is trading 76% above its estimated GF Value™ of €18.75. GuruFocus considers CareDx to be Significantly Overvalued.

Key valuation signals for STU:1K9:

  • FFO:
  • GF Value™: €18.75 vs. price of €33.00 (76% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CareDx Business Description

Other Exchanges CDNA:USA
Address 8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
73GF Score

Get the complete analysis for STU:1K9

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.00
Price
€18.75
GF Value